Ontario invests in COVID-19 test kits by Norgen Biotek
The Ontario government is supporting a $13-million investment by Norgen Biotek to scale up production of its COVID-19 saliva-based test kit, with $1 million in support through the Ontario Together Fund.
Norgen is investing in its Thorold facilities to support upgrades, modifications and equipment and production materials. The project will scale up production of COVID-19 saliva-based diagnostic kits, including the component saliva collection and preservative devices, ribonucleic acid (RNA) isolation/purification kits, and viral detection kits. Forecasted production capacity upon project completion is 100,000 diagnostic kits per day. This investment is expected to create 105 jobs.
“This program has, without a doubt, helped Norgen Biotek and many other Ontario companies overcome the challenges faced as a result of the COVID-19 pandemic,” said Yousef Haj-Ahmad, President and CEO, Norgen Biotek. “This program encouraged Norgen to undertake a broad facility expansion, a scaling up of operations, and creating new jobs to meet the demand for Norgen’s products during the pandemic.”
Established in 1998, Norgen Biotek is a biotechnology company focused on developing products for sample collection, sample preparation and sample detection, as well as providing comprehensive research services to the scientific community at its 24,000-square-feet facility.